<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic transplantation is the only curative treatment for Fanconi <z:hpo ids='HP_0001903'>anaemia</z:hpo> (FA) patients who develop <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Dose-intensive preparative regimens, to decrease disease recurrence, lead to unacceptable transplant-related toxicity in FA </plain></SENT>
<SENT sid="2" pm="."><plain>We report the outcome of three FA patients with such <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> who underwent transplantation with reduced-intensity preparative regimens </plain></SENT>
<SENT sid="3" pm="."><plain>This approach was well tolerated, even as second transplantations, and resulted in complete leukaemic remissions </plain></SENT>
<SENT sid="4" pm="."><plain>However, the graft-versus-<z:mpath ids='MPATH_336'>leukaemia</z:mpath> effect was associated with fatal <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Even after transplantation, <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> remain associated with a poor outcome in FA, and this argues in favour of early intervention when suitable donors are available </plain></SENT>
</text></document>